0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Image of the Month—Diagnosis FREE

[+] Author Affiliations

Section Editor: Carl E. Bredenberg, MD

More Author Information
Arch Surg. 2009;144(3):285-286. doi:10.1001/archsurg.2008.578-b.
Text Size: A A A
Published online

ANSWER: GASTROHEPATIC FISTULA FOLLOWING TACE FOR HCC

Transarterial chemoembolization is a commonly used treatment modality for unresectable HCC. It involves the use of transarterial catheters to deliver local high doses of chemotherapy to the tumor. Often, particulate embolic agents are also administered with the chemotherapy to eliminate the arterial vascular supply of the lesion. Transarterial chemoembolization therapy can be quite effective in treating HCC, resulting in tumor response in 16% to 61% of patients.1Data on whether TACE offers a survival benefit to patients with HCC remains somewhat controversial.2Two randomized trials3,4have suggested that there is no survival benefit, while 2 other randomized studies have reported an improvement in survival following TACE.5,6Although TACE can usually be performed safely, it can be associated with complications. The most common complication is acute liver failure secondary to hepatic necrosis. Other complications include acute renal failure, encephalopathy, and gastrointestinal bleeding. More rare ischemic complications have also been reported, including hepatic and splenic abscess, gastric and duodenal ulcerations, and biliary stricturing. Often, these complications are attributed to leaking of chemoembolic agents into collateral vessels that supply other organs outside of the tumor bed with blood.7To our knowledge, this is the first reporting of a hepatogastric fistula following TACE therapy.

This patient was discussed at the multidisciplinary tumor board with interventional radiologists, hepatobiliary surgeons, and oncologists to determine the best course of action to address the fistula. The technical details of the embolization were also reviewed. There was no concern that the chemoembolization agents had inadvertently entered the gastric vessels at the time of the initial TACE. Evaluation of the fistula defect on computed tomography (Figure 2) demonstrated that the liver was well drained into the stomach without any extravasation of enteric contents. Since the patient was clinically well with a contained fistula, it was felt that no further intervention was warranted. After discussion with the patient, surgical intervention was not recommended given the patient’s extensive medical comorbidities and his baseline poor prognosis related to his underlying cirrhosis and advanced HCC. As such, the patient was treated with palliative supportive care.

Place holder to copy figure label and caption
Figure 2.

Computed tomography of the abdomen in a patient with hepatocellular carcinoma.

Graphic Jump Location

Return to Quiz Case.

Correspondence:Timothy M. Pawlik, MD, MPH, Department of Surgery, Johns Hopkins, 600 N Wolfe St, Halsted Bldg, Room 614, Baltimore, MD 22187-6681 (tpawlik1@jhmi.edu).

Accepted for Publication:June 18, 2007.

Author Contributions:Study concept and design: Jain, Smith, and Pawlik. Acquisition of data: Jain, Smith, and Geschwind. Analysis and interpretation of data: Jain. Drafting of the manuscript: Jain, Smith, Geschwind, and Pawlik. Critical revision of the manuscript for important intellectual content: Jain and Pawlik. Administrative, technical, and material support: Smith and Geschwind. Study supervision: Pawlik.

Financial Disclosure:None reported.

Llovet  JMBruix  J Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37 (2) 429- 442
PubMed Link to Article
Cormier  JNThomas  KTChari  RSPinson  CW Management of hepatocellular carcinoma. J Gastrointest Surg 2006;10 (5) 761- 780
PubMed Link to Article
Pelletier  GRoche  AInk  O  et al.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 1990;11 (2) 181- 184
PubMed Link to Article
Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332 (19) 1256- 1261
PubMed Link to Article
Llovet  JMReal  MIMontana  X  et al. Barcelona Liver Cancer Group, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 2002;359 (9319) 1734- 1739
PubMed Link to Article
Lo  CMNgan  HTso  WK  et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 2002;35 (5) 1164- 1171
PubMed Link to Article
Marelli  LStigliano  RTriantos  C  et al.  Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30 (1) 6- 25
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 2.

Computed tomography of the abdomen in a patient with hepatocellular carcinoma.

Graphic Jump Location

Tables

References

Llovet  JMBruix  J Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37 (2) 429- 442
PubMed Link to Article
Cormier  JNThomas  KTChari  RSPinson  CW Management of hepatocellular carcinoma. J Gastrointest Surg 2006;10 (5) 761- 780
PubMed Link to Article
Pelletier  GRoche  AInk  O  et al.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 1990;11 (2) 181- 184
PubMed Link to Article
Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332 (19) 1256- 1261
PubMed Link to Article
Llovet  JMReal  MIMontana  X  et al. Barcelona Liver Cancer Group, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 2002;359 (9319) 1734- 1739
PubMed Link to Article
Lo  CMNgan  HTso  WK  et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 2002;35 (5) 1164- 1171
PubMed Link to Article
Marelli  LStigliano  RTriantos  C  et al.  Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30 (1) 6- 25
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles